Abstract
A multicohort phase 2 trial of ADT, docetaxel plus nivolumab in patients with de novo metastatic hormone-sensitive prostate cancer enriched for inflamed tumors and DNA damage repair defects.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have